Institute for Neuroimmunology and Clinical MS Research and Department of Neurology, Hamburg, Germany.
PLoS One. 2013 May 17;8(5):e59042. doi: 10.1371/journal.pone.0059042. Print 2013.
Prognostic counseling in multiple sclerosis (MS) is difficult because of the high variability of disease progression. Simultaneously, patients and physicians are increasingly confronted with making treatment decisions at an early stage, which requires taking individual prognoses into account to strike a good balance between benefits and harms of treatments. It is therefore important to understand how patients and physicians estimate prognostic risk, and whether and how these estimates can be improved. An online analytical processing (OLAP) tool based on pooled data from placebo cohorts of clinical trials offers short-term prognostic estimates that can be used for individual risk counseling.
The aim of this study was to clarify if personalized prognostic information as presented by the OLAP tool is considered useful and meaningful by patients. Furthermore, we used the OLAP tool to evaluate patients' and physicians' risk estimates. Within this evaluation process we assessed short-time prognostic risk estimates of patients with MS (final n = 110) and their physicians (n = 6) and compared them with the estimates of OLAP.
Patients rated the OLAP tool as understandable and acceptable, but to be only of moderate interest. It turned out that patients, physicians, and the OLAP tool ranked patients similarly regarding their risk of disease progression. Both patients' and physicians' estimates correlated most strongly with those disease covariates that the OLAP tool's estimates also correlated with most strongly. Exposure to the OLAP tool did not change patients' risk estimates.
While the OLAP tool was rated understandable and acceptable, it was only of modest interest and did not change patients' prognostic estimates. The results suggest, however, that patients had some idea regarding their prognosis and which factors were most important in this regard. Future work with OLAP should assess long-term prognostic estimates and clarify its usefulness for patients and physicians facing treatment decisions.
多发性硬化症(MS)的预后咨询很困难,因为疾病的进展存在高度的变异性。同时,患者和医生越来越多地需要在早期阶段做出治疗决策,这需要考虑个体的预后,以在治疗的益处和危害之间取得良好的平衡。因此,了解患者和医生如何估计预后风险,以及这些估计是否可以得到改善非常重要。基于临床试验安慰剂队列的汇总数据的在线分析处理(OLAP)工具提供了短期预后估计,可以用于个体风险咨询。
本研究旨在阐明患者是否认为 OLAP 工具提供的个性化预后信息有用且有意义。此外,我们使用 OLAP 工具评估了患者和医生的风险估计。在这个评估过程中,我们评估了多发性硬化症患者(最终 n = 110)及其医生(n = 6)的短期预后风险估计,并将其与 OLAP 的估计值进行了比较。
患者认为 OLAP 工具易于理解和接受,但仅具有中等程度的兴趣。结果表明,患者、医生和 OLAP 工具对患者疾病进展风险的评估相似。患者和医生的评估与 OLAP 工具的评估与疾病协变量的相关性最强。接触 OLAP 工具并没有改变患者的风险估计。
虽然 OLAP 工具的评估是易于理解和接受的,但它仅具有中等程度的兴趣,并且没有改变患者的预后估计。结果表明,患者对自己的预后和在这方面最重要的因素有一些了解。未来使用 OLAP 的工作应评估长期预后估计,并阐明其对面临治疗决策的患者和医生的有用性。